Evoke Pharma Statistics
Total Valuation
Evoke Pharma has a market cap or net worth of $5.20 million. The enterprise value is -$2.84 million.
Important Dates
The last earnings date was Thursday, March 13, 2025, after market close.
| Earnings Date | Mar 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Evoke Pharma has 2.07 million shares outstanding. The number of shares has increased by 583.91% in one year.
| Current Share Class | 1.49M |
| Shares Outstanding | 2.07M |
| Shares Change (YoY) | +583.91% |
| Shares Change (QoQ) | +148.25% |
| Owned by Insiders (%) | 3.92% |
| Owned by Institutions (%) | 3.95% |
| Float | 1.26M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.51 |
| Forward PS | 0.77 |
| PB Ratio | 0.79 |
| P/TBV Ratio | 0.80 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.66, with a Debt / Equity ratio of 0.73.
| Current Ratio | 1.66 |
| Quick Ratio | 1.54 |
| Debt / Equity | 0.73 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -10.38 |
Financial Efficiency
Return on equity (ROE) is -240.09% and return on invested capital (ROIC) is -44.50%.
| Return on Equity (ROE) | -240.09% |
| Return on Assets (ROA) | -26.46% |
| Return on Invested Capital (ROIC) | -44.50% |
| Return on Capital Employed (ROCE) | -72.90% |
| Revenue Per Employee | $3.42M |
| Profits Per Employee | -$1.78M |
| Employee Count | 3 |
| Asset Turnover | 0.83 |
| Inventory Turnover | 0.77 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -62.43% in the last 52 weeks. The beta is 0.12, so Evoke Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.12 |
| 52-Week Price Change | -62.43% |
| 50-Day Moving Average | 4.21 |
| 200-Day Moving Average | 4.94 |
| Relative Strength Index (RSI) | 25.49 |
| Average Volume (20 Days) | 26,843 |
Short Selling Information
The latest short interest is 20,959, so 1.01% of the outstanding shares have been sold short.
| Short Interest | 20,959 |
| Short Previous Month | 31,230 |
| Short % of Shares Out | 1.01% |
| Short % of Float | 1.66% |
| Short Ratio (days to cover) | 1.52 |
Income Statement
In the last 12 months, Evoke Pharma had revenue of $10.25 million and -$5.35 million in losses. Loss per share was -$2.81.
| Revenue | 10.25M |
| Gross Profit | 9.89M |
| Operating Income | -5.20M |
| Pretax Income | -7.13M |
| Net Income | -5.35M |
| EBITDA | n/a |
| EBIT | -5.20M |
| Loss Per Share | -$2.81 |
Full Income StatementBalance Sheet
The company has $13.60 million in cash and $5.16 million in debt, giving a net cash position of $8.44 million or $4.07 per share.
| Cash & Cash Equivalents | 13.60M |
| Total Debt | 5.16M |
| Net Cash | 8.44M |
| Net Cash Per Share | $4.07 |
| Equity (Book Value) | 7.04M |
| Book Value Per Share | 3.49 |
| Working Capital | 6.86M |
Full Balance SheetCash Flow
| Operating Cash Flow | -5.46M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
Gross margin is 96.52%, with operating and profit margins of -50.77% and -52.22%.
| Gross Margin | 96.52% |
| Operating Margin | -50.77% |
| Pretax Margin | -52.22% |
| Profit Margin | -52.22% |
| EBITDA Margin | n/a |
| EBIT Margin | -50.77% |
| FCF Margin | n/a |